Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome.
The trial further assesses Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.
Who can participate?
Individuals aged 6–25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).
What will happen in the study?
Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.
Will you/your child be paid to complete this survey?
Travel expenses will be reimbursed.
Study doctors and locations
Please fill out the form below to send your contact information to the study coordinators.
Dr. Francois Bolduc, Principal Investigator
University of Alberta/Stollery Children’s Hospital
Edmonton, Alberta, Canada
Dr. Sébastien Jacquemont, Principal Investigator
CHU Ste. Justine
Montreal, Quebec, Canada
Study Coordinators: Maryse Thibeault or Sophie Morin
View More Opportunities
An Alliant International University clinical psychology doctoral candidate is conducting a research study to learn about the cognitive profile of children with a full mutation of Fragile X. Males and transgender females between the age of 8 and 12 may be eligible to participate.
The MIND Group at the University of Minnesota is conducting a survey for parents of children with Fragile X syndrome to learn about how genetic and neurodevelopmental differences impact behavioral strengths and challenges. Parents of 3–17 year old children living with Fragile X are eligible to participate.
Purdue University is conducting a research study to learn about language and social communication development in Fragile X syndrome. Children ages 3–4 years (36–60 months) with the full mutation may be eligible to participate.
The University of Kansas Medical Center is conducting a survey to learn about the medical and mental health care needs of individuals and families affected by Fragile X syndrome, premutation carriers, and undiagnosed family members. Persons 18 years and over may be eligible.
The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with premutations of the Fragile X gene, FMR1. Individuals ages 50–80 with the FMR1 gene premutation with or without FXTAS may be eligible to participate.